Protection from spinal cord ischemia during aortic repair using a noncompetitive N-methyl-D-aspartate receptor antagonist

Sapporo Medical Journal

Volumn 65, Issue 3, 1996, Pages 179-188

  Nakamura, Masanori ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

aortic repair; dextrorphan; microdialysis; noncompetitive NMDA receptor antagonist; spinal cord ischemia

Indexed keywords

DEXTRORPHAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; AORTA CLAMPING; AORTA OCCLUSION; ARTICLE; CONTROLLED STUDY; INTRAARTERIAL DRUG ADMINISTRATION; MALE; NONHUMAN; PARAPLEGIA; RABBIT; SPINAL CORD ISCHEMIA; THORACIC AORTA;

EID: 0030511984     PISSN: 0036472X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ. Experience with 1509 patients undergoing thoracoabdominal aortic operations. J Vasc Surg 1993, 17: 357-370
2. Hollier LH, Symmonds JB, Pairolero PC, Cherry KJ, Hallett JW, Gloviezki P. Thoracoabdominal aortic aneurysm repair. Analysis of postoperative morbidity. Arch Surg 1988, 123: 871-875.
3. Cox GS, O'Hara PJ, Hertzer NR, Piedmonte MR, Krajewski LP, Beven EG. Thoracoabdominal aneurysm repair: a representative experience. J Vasc Surg 1992, 15: 780-788.
4. Livesay JJ, Cooley DA, Ventemiglia RA, Montero CG, Warrian RK, Brown DM, Duncan JM. Surgical experience in descending thoracic aneurysmectomy with and without adjuncts to avoid ischemia. Ann Thorac Surg 1985, 39: 37-46.
5. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis J. Neurochem 1984, 43: 1369-1374.
6. Choi DW. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci 1988, 11: 465-469.
7. Rokkas CK, Helfrich Jr LR, Lodner DC, Choi DW, Kouchoukos NT. Dextrorphan inhibits the release of excitatory amino acids during spinal cord ischemia. Ann Thorac Surg 1994, 58: 312-320.
8. Faden AI, Ellison JA, Noble LJ. Effects of competitive and non-competitive NMDA receptor antagonists in spinal cord injury. Eur J Pharmacol 1990, 175: 165-174.
9. DeGirolami U, Zivin JA. Neuropathology of experimental spinal cord ischemia in the rabbit. J Neuropathol Exp Neurol 1982, 41: 129-149.
10. Johnson SH, Kraimer JM, Graeber GM. Effects of flunarizine on neurological recovery and spinal cord blood flow in experimental spinal cord ischemia in rabbits. Stroke 1993, 24: 1547-1553.
11. Yum SW, Faden AI. Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK-801 and the opiate-receptor antagonist Nalmefene in experimental spinal cord ischemia. Arch Neurol 1990, 47: 277-281
12. Kitagawa K, Matsumoto M, Niinobe M, Mikoshiba K, Hata R, Ueda H, Handa N, Fukunaga R, Isaka Y, Kimura K Kamada T. Microtubule-associated protein 2 as a sensitive marker for cerebral ischemic damage-immunohistochemical investigation of dendritic damage. Neuroscience 1989, 31: 401-411.
13. Bower TC, Murray MJ, Gloviczki P, Yaksh TL, Hollier LH, Pairolero PC. Effects of thoracic aortic occlusion and cerebrospinal fluid drainage on regional spinal cord blood flow in dogs: Correlation with neurologic outcome. J Vasc Surg 1988, 9: 135-144.
14. Qayumi AK, Janusz MT, Jamieson WRE, Lyster DM. Pharmacologic interventions for prevention of spinal cord injury caused by aortic crossclamping. J Thorac Cardiovasc Surg 1992, 104: 256-261.
15. Kouchoukos NT, Wareing TH, Izumoto H, Klausing W, Abboud N. Elective hypothermic cardiopulmonary bypass and circulatory arrest for spinal protection during operations on the thoraco-abdominal aorta. J Thorac Cardiovasc Surg 1990, 99: 659-664
16. Simpson Jr RK, Robertson CS, Goodman JC. Spinal cord ischemia-induced elevation of amino acids: extracellular measurement with microdialysis. Neurochem Res 1990, 15: 635-639.
17. Regan RF, Choi DW. Glutamate neurotoxicity in spinal cord cell culture. Neuroscience 1991, 43: 585-591
18. Carpenter CL, Marks SS, Watson DL, Greenberg DA. Dextromethorphan and dextrorphan as calcium channel antagonists. Brain Res 1988, 439: 372-375.
19. Trube G, Netzer R. Dextromethorphan: Cellular effects reducing neuronal hyperactivity. Epilepsia 1994, 35 Suppl 5: s62-s67.
20. Steinberg GK, Yoon EJ, Kunis DM, Maier CM, Grant GA. Neuroprotection by N-methyl-D-aspartate antagonists in focal cerebral ischemia is dependent on continued maintenance dosing. Neuroscience 1995, 64: 99-107
21. Buchan A, Pulsinelli WA Hypothermia but not the N-methyl-D-aspartate antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia. J Neurosci 1990. 10: 311-316.
22. Steinberg GK, Kunis D, Saleh J, DeLaPaz R. Protection after transient focal cerebral ischemia by the N-methyl-D-aspartate antagonist Dextrorphan is dependent upon plasma and brain levels. J Cereb Blood Flow Metab 1991, 11: 1015-1024.
23. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM. Saftey, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patents with acute stroke. Stroke 1995, 26: 254-258.
24. Hargreaves RJ, Hill RG, Iversen LL. Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology. Acta Neurochir 1994, 60: 15-19.